Raw Steroid Powders Female Sex Enhancement Raw Powder Flibanserin For Women Sex

Flibanserin Quick Details:

·Flibanserin Product name: Flibanserin
·Flibanserin Synonyms: Centrophenoxine hydrochloride; 4-Chlorophenoxy-acetic acid 2-(dimethylamino)ethyl ester hydrochloride
·Flibanserin CAS No.: 167933-07-5
·Flibanserin EINECS: 222-975-3
·Flibanserin Molecular Formula: C20H21F3N4O
·Flibanserin Molecular Weight:294.17
·Flibanserin Appearance: White crystalline powder
·Flibanserin Assay: 99%
·Flibanserin Usage: Pharmaceutical raw intermediates

Flibanserin Description:

Part of a class of drugs known as nootropic drugs - or 'smart drugs', Centrophenoxine is one of the original anti-ageing, neuro-energizing drugs.
The word nootropic itself is derived from the Greek words 'noos' or 'mind' and 'tropein', which means bend or turn.
Centrophenoxine is an anti-ageing drug, widely used to increase brain energy. It has been found to be extremely effective in the treatment of brain damage due to old age, stroke or toxic chemicals.
Centrophenoxine is used to enhance the body's defense against free radical damage caused by ageing. It is particularly useful in the treatment of senile dementia, where regular use can prevent further mental deterioration.
Often referred to as an 'ageing reversal drug', Centrophenoxine has been clinically proven to improve memory and increase the speed at which new information is stored and used. It is effective in fighting both cerebral ageing and age-related diseases.

Flibanserin is used for hypoactive sexual desire disorder among women. Those receiving flibanserin report that the average number of times they had "satisfying sexual events" rose from 2.8 to 4.5 times a month. However, women receiving placebo reported also an increase of "satisfying sexual events" from 2.7 to 3.7 times a month. Evaluation of the overall improvement of their condition and whether the benefit was meaningful to the women, showed a significantly higher rate of a meaningful benefit in the flibanserin-treated people versus the placebo group. The onset of the flibanserin effect was seen from the first timepoint measured after 4 weeks of treatment and maintained throughout the treatment period.

The effectiveness of flibanserin was evaluated in three phase 3 clinical trials. Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire.

All three trials showed that flibanserin produced a statistically significant increase in the number of SSEs and reduced distress related to sexual desire.

Flibanserin COA